204 related articles for article (PubMed ID: 8019715)
21. Determination of molecular marker expression can predict clinical outcome in colon carcinomas.
Galizia G; Lieto E; Ferraraccio F; Orditura M; De Vita F; Castellano P; Imperatore V; Romano C; Ciardiello F; Agostini B; Pignatelli C
Clin Cancer Res; 2004 May; 10(10):3490-9. PubMed ID: 15161706
[TBL] [Abstract][Full Text] [Related]
22. Staging of carcinoma of the colon and rectum.
Roseman DL; Straus AK
Surg Gynecol Obstet; 1980 Jul; 151(1):93-5. PubMed ID: 7384992
[TBL] [Abstract][Full Text] [Related]
23. Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
Wang WS; Chen PM; Chiou TJ; Liu JH; Fan FS; Lin TC; Jiang JK; Yang SH; Yen CC; Wang HS; Lin JK
Hepatogastroenterology; 2000; 47(36):1590-4. PubMed ID: 11149009
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of nuclear morphometry in colorectal cancer.
Fernández-López F; Paredes-Cotoré JP; Cadarso-Suárez C; Forteza-Vila J; Puente-Domínguez JL; Potel-Lesquereux J
Dis Colon Rectum; 1999 Mar; 42(3):386-92. PubMed ID: 10223762
[TBL] [Abstract][Full Text] [Related]
26. [Global prognosis and stage classification of colorectal carcinoma].
Terrazas Hontañón JM; Val Bernal JF; Buelta Carrillo L
Rev Esp Oncol; 1985; 32(2):323-41. PubMed ID: 3843465
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of human telomerase reverse transcriptase in patients with colon cancer].
Li LR; Wan DS; Pan ZZ; Hardingham J; Rieger N; Hewett P; Zhou ZW; Chen G
Ai Zheng; 2004 Nov; 23(11 Suppl):1502-7. PubMed ID: 15566667
[TBL] [Abstract][Full Text] [Related]
28. [Did the stage of diagnosis and the surgical management of colonic cancers change over the last ten years? Apropos of 303 patients].
Sales JP; Parc R
Ann Chir; 1994; 48(7):591-5. PubMed ID: 7864533
[TBL] [Abstract][Full Text] [Related]
29. A modification of the Dukes' classification of carcinoma of the colon and rectum.
Smith LA; Masood S; Jagadish B; Saffos RO; Rhatigan RM; Stephenson SE
Am Surg; 1978 Feb; 44(2):94-7. PubMed ID: 626441
[No Abstract] [Full Text] [Related]
30. [Study on the prognostic factors of colorectal cancer after radical resection and on suggested model for prediction].
Yang YF; Li PZ; Liang XB; Han XL; Li YP; Cong J
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Mar; 26(3):214-7. PubMed ID: 15941514
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
32. The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival.
Murphy J; O'Sullivan GC; Lee G; Madden M; Shanahan F; Collins JK; Talbot IC
Am J Gastroenterol; 2000 Dec; 95(12):3607-14. PubMed ID: 11151900
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials.
Wolmark N; Fisher B; Wieand HS
Ann Surg; 1986 Feb; 203(2):115-22. PubMed ID: 3511864
[TBL] [Abstract][Full Text] [Related]
34. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Mulder WM; Stern PL; Stukart MJ; de Windt E; Butzelaar RM; Meijer S; Adér HJ; Claessen AM; Vermorken JB; Meijer CJ; Wagstaff J; Scheper RJ; Bloemena E
Clin Cancer Res; 1997 Nov; 3(11):1923-30. PubMed ID: 9815581
[TBL] [Abstract][Full Text] [Related]
35. Dukes' classification as a prognostic factor in patients with squamous cell carcinoma of the thoracic esophagus undergoing combined-modality treatment.
Dabrowski A; Skoczylas T; Ciechański A; Wallner G; Zinkiewicz K; Cwik G; Górczyński R; Borowski A
Med Sci Monit; 2006 Oct; 12(10):CR409-15. PubMed ID: 17006399
[TBL] [Abstract][Full Text] [Related]
36. Neopterin and prognosis in patients with adenocarcinoma of the colon.
Weiss G; Kronberger P; Conrad F; Bodner E; Wachter H; Reibnegger G
Cancer Res; 1993 Jan; 53(2):260-5. PubMed ID: 8417818
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the prognostic accuracy of Astler-Coller's and Jass' classifications of colorectal cancer.
Li Destri G; Rinzivillo C; Vasquez E; Di Cataldo A; Puleo S; Licata A
Tumori; 2001; 87(3):127-9. PubMed ID: 11504364
[TBL] [Abstract][Full Text] [Related]
38. A Dukes/Jass combination--is it more discriminating?
Haslam AC; Pearson JM; Bisset DL; Michie HR; Hobbiss JH
Colorectal Dis; 2006 Jun; 8(5):418-22. PubMed ID: 16684086
[TBL] [Abstract][Full Text] [Related]
39. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
40. From Dukes through Jass: pathological prognostic indicators in rectal cancer.
Harrison JC; Dean PJ; el-Zeky F; Vander Zwaag R
Hum Pathol; 1994 May; 25(5):498-505. PubMed ID: 8200644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
